Investor Presentaiton

Sintilimab: the Only PD-1 inhibitor Proven to be Efficacious in the First-line Treatment of Five Major Types of Cancer 1 1L Nonsquamous NSCLC 2 1L Squamous NSCLC 3 1L HCC 4 1L ESCC 5 1L GC One of the few PD-1s approved for two 1L indications of NSCLC ORIENT-11 Study 2020.01: met primary endpoint 2021.02: SNDA approved in China 2021.05: US BLA accepted primarily based on ORIENT-11 data ORIENT-12 Study 2020.05: met primary endpoint 2021.06: SNDA approved in China Worldwide first PD-1 based combination therapy succeeded in 1L HCC ORIENT-32 Study 2020.09: met primary endpoint of OS 2021.06: SNDA approved in China First China-originated PD-1 succeeded in a global Phase 3 for 1L ESCC ORIENT-15 Study Global MRCT Phase 3 study 2021.06: met primary endpoint of OS regardless of PD-L1 expression ESMO 2021: Results to Release By end 2021: Plan to file sNDA to the NMPA Worldwide one of the only two PD-1s succeeded 1L GC ORIENT-16 Study 2021.08: met primary endpoint of OS in both ITT group and PD-L1 positive group ESMO 2021: Results to Release By end 2021: Plan to file sNDA to the NMPA Sintilimab is the only PD-1 inhibitor proven to be efficacious in the first-line treatment of five major types of cancer, which account for about 2.0m new cancer cases in China or 4.8m globally each year. Innovent Confidential Copyright©2021 Innovent Biologics 19

View entire presentation